Literature DB >> 168249

Epidemiological studies of Epstein-Barr herpesvirus infection in Western Australia.

P K Lai, E M Mackay-Scollay, M P Alpers.   

Abstract

In a study of a Caucasian population in Western Australia the prevalence of antibodies to Epstein-Barr virus (EBV) was 41% in the 9- to 10-year age group, 80% in the 16 to 19-year age group and 92% in young adults. The age-specific annual seroconversion rates indicated two peaks of primary EBV infection in the population studied - one under 5 years of age and the other at adolescence. The geometric mean titre rose with age, from 23 at 5-6 years to 53 at 36-40 years. It was shown that in 73 families studied there was evidence of probable spread of EBV infection among siblings, particularly between those of the same sex. Serological study of patients with infectious mononucleosis indicated that 100% of those examined had antibody to EBV and the geometric mean titre was elevated to 210. Rising titres and seroconversion was demonstrated in these patients together with successful establishment of EBV-carrying cell lines from the peripheral blood in two-thirds of the cases.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 168249      PMCID: PMC2130598          DOI: 10.1017/s0022172400046842

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  15 in total

1.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA.

Authors:  M A EPSTEIN; B G ACHONG; Y M BARR
Journal:  Lancet       Date:  1964-03-28       Impact factor: 79.321

2.  Responses of gibbons to inoculation of Epstein-Barr virus.

Authors:  J Werner; C A Pinto; R F Haff; W Henle; G Henle
Journal:  J Infect Dis       Date:  1972-12       Impact factor: 5.226

3.  Prolonged oropharyngeal excretion of Epstein-Barr virus after infectious mononucleosis.

Authors:  G Miller; J C Niederman; L L Andrews
Journal:  N Engl J Med       Date:  1973-02-01       Impact factor: 91.245

4.  Prevalence of antibodies to Epstein-Barr virus, cytomegalovirus and Toxoplasma in a Mexican highland community.

Authors:  R Golubjatnikov; V D Allen; M Steadman; S L Inhorn
Journal:  Am J Epidemiol       Date:  1973-02       Impact factor: 4.897

5.  Prevalence, incidence and persistence of EB virus antibody in young adults.

Authors:  J C Niederman; A S Evans; L Subrahmanyan; R W McCollum
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

6.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

7.  A lymphoblastoid cell line derived from cells of myeloid leukemia by infection with the Epstein-Barr herpes virus.

Authors:  P K Lai; J M Papadimitriou; D W Kennett; E M Mackay-Scollay; M P Alpers
Journal:  Cytobios       Date:  1973-11

8.  Prevalence of antibodies to EB virus and other herpesviruses.

Authors:  D D Porter; I Wimberly; M Benyesh-Melnick
Journal:  JAMA       Date:  1969-06-02       Impact factor: 56.272

9.  Immunofluorescence, interference, and complement fixation technics in the detection of the herpes-type virus in Burkitt tumor cell lines.

Authors:  G Henle; W Henle
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701

10.  Epstein-Barr virus. Heterophile responses in squirrel monkeys inoculated with virus-transformed autologous leukocytes.

Authors:  T Shope; G Miller
Journal:  J Exp Med       Date:  1973-01-01       Impact factor: 14.307

View more
  5 in total

1.  Development of cell-mediated immunity to Epstein-Barr herpesvirus in infectious mononucleosis as shown by leukocyte migration inhibition.

Authors:  P K Lai; M P Alpers; E M MacKay-Scollay
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

2.  Epidemiology of Epstein-Barr virus infection in pre-adolescent children: application of a new salivary method in Edinburgh, Scotland.

Authors:  N S Crowcroft; A Vyse; D W Brown; D P Strachan
Journal:  J Epidemiol Community Health       Date:  1998-02       Impact factor: 3.710

3.  Relationship of in vitro immune responses to Epstein-Barr herpesvirus and severity of infectious mononucleosis.

Authors:  K Goldstein; P K Lai; M Lightfoote; A P Andrese; D Fuccillo; R J Connor; P H Levine
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

4.  Andrographolide Inhibits Epstein-Barr Virus Lytic Reactivation in EBV-Positive Cancer Cell Lines through the Modulation of Epigenetic-Related Proteins.

Authors:  Praphatson Malat; Tipaya Ekalaksananan; Chukkris Heawchaiyaphum; Supawadee Suebsasana; Sittiruk Roytrakul; Yodying Yingchutrakul; Chamsai Pientong
Journal:  Molecules       Date:  2022-07-21       Impact factor: 4.927

5.  High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi.

Authors:  Nathan D Montgomery; Cara Randall; Matthew Painschab; Ryan Seguin; Bongani Kaimila; Edwards Kasonkanji; Takondwa Zuze; Robert Krysiak; Marcia K Sanders; Avian Elliott; Melissa B Miller; Coxcilly Kampani; Fred Chimzimu; Maurice Mulenga; Blossom Damania; Tamiwe Tomoka; Yuri Fedoriw; Dirk P Dittmer; Satish Gopal
Journal:  Cancer Med       Date:  2019-11-29       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.